000141761 001__ 141761
000141761 005__ 20240229112526.0
000141761 0247_ $$2doi$$a10.1007/s11060-018-03018-6
000141761 0247_ $$2pmid$$apmid:30446899
000141761 0247_ $$2ISSN$$a0167-594X
000141761 0247_ $$2ISSN$$a0167-594x
000141761 0247_ $$2ISSN$$a1573-7373
000141761 0247_ $$2altmetric$$aaltmetric:51295850
000141761 037__ $$aDKFZ-2018-02030
000141761 041__ $$aeng
000141761 082__ $$a610
000141761 1001_ $$aTegeder, Isabel$$b0
000141761 245__ $$aFunctional relevance of genes predicted to be affected by epigenetic alterations in atypical teratoid/rhabdoid tumors.
000141761 260__ $$aDordrecht [u.a.]$$bSpringer Science + Business Media B.V$$c2019
000141761 3367_ $$2DRIVER$$aarticle
000141761 3367_ $$2DataCite$$aOutput Types/Journal article
000141761 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1554293283_19886
000141761 3367_ $$2BibTeX$$aARTICLE
000141761 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141761 3367_ $$00$$2EndNote$$aJournal Article
000141761 520__ $$aAtypical teratoid/rhabdoid tumor (ATRT) is a highly malignant brain tumor predominantly arising in infants. Mutations of SWI/SNF chromatin remodeling complex members SMARCB1/INI1 or (rarely) SMARCA4/Brg1 are the sole recurrent genetic lesions. Epigenetic studies revealed a large number of genes predicted to be affected by differential histone modifications in ATRT, but the role of these genes in the biology of ATRT remains uncertain. We therefore aimed at exploring the role of these genes in the detrimental effects of SMARCB1-deficiency.The functional relevance of 1083 genes predicted to be affected by epigenetic alterations in ATRT was examined in vivo using a Drosophila melanogaster model of SMARCB1-deficiency. Human orthologues of genes whose knockdown modified the phenotype in the Gal4-UAS fly model were further examined in ATRT samples and SMARCB1-deficient rhabdoid tumor cells.Knockdown of Snr1, the fly orthologue of SMARCB1, resulted in a lethal phenotype and epigenetic alterations in the fly model. The lethal phenotype was shifted to later stages of development upon additional siRNA knockdown of 89 of 1083 genes screened in vivo. These included TGF-beta receptor signaling pathway related genes, e.g. CG10348, the fly orthologue of transcriptional regulator PRDM16. Subsequently, PRDM16 was found to be over-expressed in ATRT samples and knockdown of PRDM16 in SMARCB1-deficient rhabdoid tumor cells reduced proliferation.These results suggest that a subset of genes affected by differential histone modification in ATRT is involved in the detrimental effects of SMARCB1-deficiency and also relevant in the biology of ATRT.
000141761 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000141761 588__ $$aDataset connected to CrossRef, PubMed,
000141761 7001_ $$aThiel, Katharina$$b1
000141761 7001_ $$0P:(DE-He78)df8660bc5aba525f7fb6dba4aac15c1c$$aErkek, Serap$$b2$$udkfz
000141761 7001_ $$0P:(DE-He78)3fdc3623477264cb5d0e14f256dbfbb8$$aJohann, Pascal$$b3$$udkfz
000141761 7001_ $$aBerlandi, Johannes$$b4
000141761 7001_ $$0P:(DE-He78)26c413e17f63cb683978f4025fcb831e$$aThatikonda, Venu$$b5$$udkfz
000141761 7001_ $$aFrühwald, Michael C$$b6
000141761 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b7$$udkfz
000141761 7001_ $$aJeibmann, Astrid$$b8
000141761 7001_ $$00000-0003-2707-8484$$aHasselblatt, Martin$$b9
000141761 773__ $$0PERI:(DE-600)2007293-4$$a10.1007/s11060-018-03018-6$$n1$$p43-55$$tJournal of neuro-oncology$$v141$$x1573-7373$$y2019
000141761 909CO $$ooai:inrepo02.dkfz.de:141761$$pVDB
000141761 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)df8660bc5aba525f7fb6dba4aac15c1c$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000141761 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3fdc3623477264cb5d0e14f256dbfbb8$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000141761 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)26c413e17f63cb683978f4025fcb831e$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000141761 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000141761 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000141761 9141_ $$y2019
000141761 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000141761 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEURO-ONCOL : 2017
000141761 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141761 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141761 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000141761 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141761 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000141761 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141761 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141761 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000141761 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000141761 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000141761 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000141761 980__ $$ajournal
000141761 980__ $$aVDB
000141761 980__ $$aI:(DE-He78)B062-20160331
000141761 980__ $$aI:(DE-He78)L101-20160331
000141761 980__ $$aUNRESTRICTED